Versant-backed Tempest grabs a $70M round with plans to drive a slate of I/O drugs into the clinic
The booming cancer drug R&D field can count one more player with some big dreams to pursue in immuno-oncology.
San Francisco-based Tempest Therapeutics is making …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
